Skip to main content
XLO
NASDAQ Life Sciences

Xilio Extends Cash Runway to Early 2028, Advances Key Cancer Drug Pipeline

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$7.82
Mkt Cap
$44.699M
52W Low
$6.465
52W High
$16.52
52W Position info
21% above low
Off High info
53% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

XLO sits 21% above its 52-week low of $6.465.

Summary

Xilio Therapeutics announced its first-quarter 2026 financial results and provided significant business and pipeline updates. Crucially, the company achieved a development milestone under its collaboration with AbbVie, which has extended its cash runway into early 2028, a material improvement from the end of 2027 reported in the last 10-K. This enhanced financial stability is critical for a clinical-stage biotechnology company. Additionally, Xilio reported strong progress across its pipeline, including being on track for an IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501. New preclinical data for XTX601 were presented at AACR, and another multi-specific T cell engager program is advancing. These updates provide positive momentum and de-risk the company's near-term operations, making the stock more attractive to investors. Traders will be watching for the upcoming IND submission and Phase 1 trial initiations as key catalysts.

At the time of this announcement, XLO was trading at $7.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.7M. The 52-week trading range was $6.47 to $16.52. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

XLO - Latest Insights

XLO
Aug 17, 2026, 7:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.17
Real-time Price: $8.70 info
Change: -$0.470 (-5%) info
Market Cap: $57.247M info
XLO
Aug 12, 2026, 7:40 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.20
Real-time Price: $8.70 info
Change: -$0.500 (-5%) info
Market Cap: $57.247M info
XLO
Aug 12, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.20
Real-time Price: $8.70 info
Change: -$0.500 (-5%) info
Market Cap: $57.247M info
XLO
Aug 12, 2026, 7:34 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $9.20
Real-time Price: $8.70 info
Change: -$0.500 (-5%) info
Market Cap: $57.247M info
XLO
Jun 12, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.31
Real-time Price: $8.70 info
Change: +$0.390 (+5%) info
Market Cap: $57.247M info